Dannielle Appelhans - 09 Aug 2022 Form 4 Insider Report for Rubius Therapeutics, Inc.

Role: Chief Operating Officer
Signature: /s/ Maiken Keson-Brookes, as Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 09 Aug 2022
Net transactions value: -$4,590
Form type: 4
Filing time: 12 Aug 2022, 15:06:56 UTC
Previous filing: 19 Jul 2022
Next filing: 01 Feb 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RUBY	Common Stock	Options Exercise		+12,500			12,500	09 Aug 2022	Direct	F1
transaction	RUBY	Common Stock	Sale	$4,590	-5,737	-46%	$0.8000^*	6,763	10 Aug 2022	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RUBY	Restricted Stock Units	Options Exercise	$0	-12,500	-25%	$0.000000	37,500	09 Aug 2022	Common Stock	12,500		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2	Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units listed in Table II. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the reporting person.
F3	The shares underlying the restricted stock units vest in four equal annual installments beginning on August 9, 2022.